NetworkNewsWire Releases Exclusive Audio Interview with PreveCeutical Medical Inc. (CSE:PREV) (OTCQB:PRVCF) (FSE:18H)
NEW YORK , June 26, 2018 (GLOBE NEWSWIRE) -- NetworkNewsAudio, via NetworkNewsWire (“NNW”), a multifaceted financial news and publishing company that delivers a new generation of social communication solutions for business, today announces the online availability of its interview with PreveCeutical Medical Inc. (CSE:PREV) (OTCQB:PRVCF) (FSE:18H), a client of NNW positioned in rapidly-growing markets with innovative preventative therapies and a groundbreaking cannabidiol (“CBD”) drug delivery platform.
The interview can be heard at http://nnw.fm/gXMx8
NNW’s Stuart Smith introduces PreveCeutical’s Chairman, CEO and President Stephen Van Deventer in an interview that highlights the company’s business model, products, and R&D programs designed to provide next-generation preventative therapies.
PreveCeutical began as a platform to capitalize on the $3.8 trillion preventative health sector and to take advantage of the largely untapped industry through combining pharmaceuticals and natural products. The company coined the phrase “PreveCeutical” with the intention to research, develop and market products designed with innovative delivery technologies and a focus on preventative health.
Based on this premise, the company’s CELLB9® is a nutraceutical product infused with select peptides from the venom of the Caribbean blue scorpion. PreveCeutical intends to create a synthetic pharmaceutical version of the venom to provide consistency for replication. The efforts also aim to produce a cost-effective alternative as compared to scorpion venom which, Van Deventer states is, “one of the most expensive liquids on earth.”
PreveCeutical is also focused on its dual gene therapy for the treatment of diabetes and obesity, as well as on the advancement of its Sol-Gel platform, a soluble gel in liquid form infused with cannabinoids. The Sol-Gel platform is designed to provide relief across a variety of indications, including seizures. Based on growing evidence that cannabinoids are helpful in the treatment of seizures, PreveCeutical’s Sol-Gel takes treatment a step further with a focus on prevention.
Lastly, PreveCeutical is focused on another R&D project designed to provide pain relief, which, the company believes “will be stronger than morphine or any of the opioids out there today.” As well as its potency, the product is designed to eliminate adverse side effects while providing a non-psychoactive, non-addictive alternative option for consumers.
Van Deventer also provides an overview of PreveCeutical’s leadership team, which boasts extensive experience in business and product development, corporate strategy, and capital markets. He also highlights the company’s science and research team, which has decades of combined experience in product creation through FDA approval and commercialization. The team also incorporates expertise in the development of next-generation drug technologies and preventative treatment alternatives that are comparable to highly-expensive treatments (i.e., gene therapy) to be offered at a fraction of the cost.
Throughout the remainder of 2018 and moving forward, PreveCeutical is focused on key acquisitions and the pursuit of assets/preventative products that are commercially viable in order to create a strong and diverse revenue stream. Additionally, the company is working toward achievement of several milestones within its R&D pipeline with intention to advance future clinical trials of its products.
In conclusion, Van Deventer discusses PreveCeutical’s strategic partnership with Aurora Cannabis (ACBFF) (ACB), a leading producer and distributor of high-grade medical cannabis. Van Deventer describes the relationship as key to PreveCeutical in securing supply of cannabinoids that are consistent and of the highest quality.
About PreveCeutical Medical Inc.
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Program; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). PreveCeutical sells CELLB9®, an Immune System Booster. CELLB9® is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. This product is available on the company’s website.
For more information, visit the company’s website at http://www.PreveCeutical.com
About NetworkNewsAudio
NetworkNewsAudio, a service of NetworkNewsWire (NNW), allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded companies we're watching. The audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio is a Brand Awareness Distribution Solution from NetworkNewsWire.
For more information, visit: http://www.NetworkNewsAudio.com
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge. For more information, please visit https://www.NetworkNewsWire.com.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.
Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
© 2018 GlobeNewswire, Inc. All Rights Reserved.
